Cutler Group LP Arcus Biosciences, Inc. Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	BUY	$15.96 - $23.15 $12,927 - $18,751	810 Added 207.69%	1,200 $21,000
Q4 2022 Feb 07, 2023	SELL	$19.7 - $35.71 $2,167 - $3,928	-110 Reduced 22.0%	390 $8,000
Q3 2022 Oct 25, 2022	SELL	$23.23 - $30.07 $109,599 - $141,870	-4,718 Reduced 90.42%	500 $13,000
Q2 2022 Aug 04, 2022	BUY	$17.23 - $37.73 $77,845 - $170,464	4,518 Added 645.43%	5,218 $132,000
Q1 2022 Apr 14, 2022	BUY	$28.92 - $41.83 $17,352 - $25,098	600 Added 600.0%	700 $22,000
Q4 2021 Jan 18, 2022	SELL	$31.38 - $48.47 $3,138 - $4,847	-100 Reduced 50.0%	100 $4,000
Q3 2021 Oct 26, 2021	SELL	$26.93 - $37.68 $16,158 - $22,608	-600 Reduced 75.0%	200 $6,000
Q2 2021 Jul 19, 2021	BUY	$22.75 - $35.77 $6,825 - $10,731	300 Added 60.0%	800 $21,000
Q1 2021 Apr 26, 2021	BUY	$26.16 - $41.39 $13,080 - $20,695	500 New	500 $14,000
Q3 2020 Oct 27, 2020	SELL	$17.14 - $25.47 $1,714 - $2,547	-100 Closed	0 $0
Q2 2020 Jul 22, 2020	SELL	$13.97 - $36.56 $2,794 - $7,312	-200 Reduced 66.67%	100 $2,000
Q1 2020 May 07, 2020	BUY	$8.78 - $19.28 $2,634 - $5,784	300 New	300 $4,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.12B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.